Diadem S.p.A. a yau ta sanar da rufe kaso na farko na samar da kudaden shiga na Euro miliyan 10. Sabon mai saka hannun jari CDP Venture Capital ne ke jagorantar zagayen tallafin da mai saka hannun jari na Panakès Partners. Sabon tallafin ya biyo bayan sanarwar da Diadem da Bankin Zuba Jari na Turai (EIB) suka yi a farkon wannan watan cewa EIB ta bai wa Diadem lamuni na kasuwanci Yuro miliyan 7.5.
Diadem za ta yi amfani da sabon kuɗin don ci gaba da kasuwancin duniya da kuma ƙarin tabbatar da asibiti na AlzoSure® Predict, gwajin jini na biomarker wanda ba shi da haɗari wanda zai iya ganewa tare da babban daidaito ko mutanen da suka wuce shekaru 50 tare da alamun rashin fahimta za su ko ba za su iya ba. ci gaba zuwa cutar Alzheimer har zuwa shekaru shida kafin ingantattun alamun bayyanar su bayyana. Amfaninsa yana da goyan bayan bayanan asibiti daga babban binciken dogon lokaci wanda shine tushen AlzoSure® Predict kwanan nan ya sami alamar CE-IVD da ƙirar Na'urar Breakthrough daga Hukumar Abinci da Magunguna ta Amurka.
"Diadem kyakkyawan misali ne na sabbin masana'antu: fasaha ta musamman, wacce aka haɓaka a Jami'ar Brescia, cibiyar bincike ta ci gaba, kuma tana ba da damar shiga tsakani a farkon matakan cututtukan cututtukan, lokacin da damar samun nasarar shiga tsakani. sun fi girma, "in ji Enrico Resmini, Shugaba da Babban Manajan CDP Venture Capital. "Mun gamsu sosai da saka hannun jari a Diadem, wanda kuma ya cika ka'idojin tasirin zamantakewa da karfafa bincike a fannin kimiyyar rayuwa."
Diana Saraceni, Wanda ya kafa kuma Manajan Abokin Abokin Hulɗa na Panakes, ta ce, “Mun yi farin cikin sabunta jarinmu a Diadem, wanda fasahar juyin juya hali wacce fasahar juyin juya hali ke da yuwuwar canza tsarin kula da cutar Alzheimer, wani mummunan yanayi tare da tsada mai yawa ga mutum da kuma al'umma. . Diadem ya sami babban ci gaba wajen haɓaka fasahar ta AlzoSure tun lokacin da muka saka hannun jari na farko, samar da ingantaccen ingantaccen bayanan asibiti, haɓaka samfuran darajar kasuwanci, samun takaddun shaida da kyaututtuka masu mahimmanci, da gina tushe don cin nasarar kasuwancin duniya cikin haɗin gwiwa tare da abokan hulɗa. Ya fito a matsayin jagora a cikin muhimmin filin bincike na novel biomarker, kuma muna alfahari da jagorantar wannan zagaye na kudade. "
"Muna maraba da goyon bayan wadannan fitattun kungiyoyin manyan kamfanoni, wadanda ke raba ra'ayinmu game da duniyar da alamun farko na rashin fahimta shine kira zuwa mataki, ba hukuncin kisa ba," in ji Dr. Gerald Möller, Shugaban Hukumar Diadem. . "A karkashin jagorancin Paul Kinnon na kwarai, Diadem za ta yi amfani da kudaden don kara fadada kungiyar ta duniya don tallafawa binciken mu na musamman wanda zai iya kawo sauyi a fagen Alzheimer. Wannan kudade tare da yarjejeniyar lamuni ta EIB da aka sanar kwanan nan za ta samar da Diadem tare da babban birnin don tallafawa kamfanin yayin da yake tallata AlzoSure® Predict da kuma gina kasuwancin duniya mai nasara."
Diadem yana haɓaka ƙimar AlzoSure® Predict a matsayin gwaji mai sauƙi, wanda ba mai cutarwa ba wanda ba ya cutar da ƙwayar cuta ta ƙwayar cuta don yin hasashen yiwuwar yiwuwar mai haƙuri sama da shekaru 50 tare da nakasar fahimi zai ci gaba zuwa cutar ta Alzheimer. Fasahar kamfanin tana amfani da hanyar nazari wanda ya haɗa da ƙwararriyar rigakafin da Diadem ta haɓaka kuma an tsara shi don ɗaure zuwa U-p53AZ da jerin abubuwan da aka yi niyya. U-p53AZ shine bambance-bambancen nau'in furotin na p53 wanda ke da tasiri a cikin pathogenesis na AD a cikin binciken da yawa.
Ga CDP Venture Capital, Mario Scuderi da Gregorio Gaspari ne suka kula da aikin, bi da bi da kuma manazarta na Asusun Juyin Halitta.
